BioSenic S.A. (FRA:BT1)

Germany flag Germany · Delayed Price · Currency is EUR
0.0021
-0.0002 (-8.70%)
At close: Jan 30, 2026
-82.93%
Market Cap1.57M -21.5%
Revenue (ttm)-2.39M -69.6%
Net Income-4.00M
EPS-0.01
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume12,396
Open0.0021
Previous Close0.0023
Day's Range0.0021 - 0.0021
52-Week Range0.0010 - 0.0057
Betan/a
RSI48.31
Earnings DateApr 27, 2026

About BioSenic

BioSenic S.A., a biotechnology company, develops cell therapy products and treatments for autoimmune and inflammatory diseases in Belgium and France. The company offers arsenic trioxide (ATO) and oral arsenic trioxide (OATO) platforms. It also provides medicinal products, including ArsciMed, an intravenous drug to treat autoimmune diseases. In addition, the company develops 4P004v which is in Phase I clinical trial for veterinary use. BioSenic S.A. is headquartered in Saintes, Belgium. [Read more]

Industry Biological Products, Except Diagnostic Substances
CEO Jean-Luc Vandebroek
Employees 7
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol BT1
Full Company Profile

Financial Performance

In 2024, BioSenic's revenue was 102,000, a decrease of -69.64% compared to the previous year's 336,000. Losses were -4.77 million, -83.43% less than in 2023.

Financial Statements